1. Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the Spike/ACE2 interaction and the Papain-like Protease PLpro  Gil-Moles, M.; Türck, S. ; Basu, U. ; Pettenuzo, A. ; Ott, I. and others Chem. Eur. J., 2021, 27, 17928-17940. [Link]
2. A new family of anticancer candidates:   synthesis, characterization and exploration of the antiproliferative properties Khodjoyan, S.; Remadna, E.; Dossmann, H.; Lesage, D.; Gontard, G.; Forte, J.; Hoffmeister, H.; Basu, U.; Ott, I.; Spence, P.; Waller, Z. A. E.; Salmain, M.; Bertrand , B. Chem. Eur. J., 2021, 27, 15573-15785. [Link]
3. Are Pt (IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? Schmidt, C; Babu, T; Kostrhunova, H; Timm, A; Basu, U; Ott, I; Gandin, V; Brabec, V; Gibson, D J. Med. Chem., 2021, 64, 11364–11378. [Link]
4. Rollover Cyclometalation vs Nitrogen Coordination in Tetrapyridyl Anticancer Gold(III) Complexes: Effect on Protein Interaction and Toxicity Zhou, X.; Carbo-Bague, I.; Siegler, M. A.; Hilgendorf, J.; Basu, U.; Ott, I.; Liu, R.; Zhang, L.;  Ramu, V.; IJzerman, A. P.; Bonnet, S. JACS Au 2021, 1,  380–395. [Link]
5. Recent Advances in the Chemistry of Iron-based Chemotherapeutic Agents Basu, U.; Roy, M.; Chakravarty, A.R. Coord. Chem. Rev. 2020, 417, 213339 [Link]
6. Gold Metallodrugs to Fight the Corona Virus: Inhibitory Effects on the SpikeACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics Gil-Moles, M.; Basu, U.; Büssing, R.; Hoffmeister, H.; Türck, S.; Varchmin, A.; Ott, I. Chem. Eur. J. 2020, 26, 15140-15144. [Link]
7. Discovery of neutral palladium-oxo clusters Pd16 and Pd24 and their supramolecular interactions Bhattacharya, S.; Basu, U.; Haouas, M.; Su, P.; Espenship, M. F.; Wang, F.; Solé-Daura, A.; Taffa, D. H.; Wark, M.; Poblet, J. M.; Laskin, J.; Cadot, E.; Kortz, U. Angew. Chem. Int. Ed. 2020, 60, 3632-3639. [Link]
8. A Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as Potential Chemotherapeutic Agent: From Synthesis to In Vivo Studies Notaro, A.; Frei, A; Rubbiani, R.; Jakubaszek, M.; Basu, U.; Koch, S.; Mari, C.; Dotou, M.; Blacque, O.; Gouyon, J.; Bedioui, F.; Rotthowe, N.; Winter, R.; Goud, B.; Ferrari, S.; Tharaud, M.; Rezácová, M.; Humajová, J.; Tomšík, P.; Gasser, G. J. Med. Chem. 2020, 63, 5568–5584. [Link]
9. An Erlotinib gold (I) conjugate for combating triple-negative breast cancer Ortega, E.; Zamora, A.; Basu, U.; Lippmann, P.; Rodríguez, V.; Janiak, C.; Ott, I.; Ruiz, J. J. Inorg. Biochem. 2020, 203, 110910 [Link]
10. NHC-gold compounds mediate immune suppression through induction of AHR-TGFβ1 signaling in vitro and in scurfy mice Cheng, X.; Haeberle, S.; Shytaj, I. L.; Gama-Brambila, R.A; Theobald, J.; Ghafoory, S.; Wölker, J.; Basu, U.; Schmidt, C.; Timm, A.; Taškova, K.; Bauer, A.S; Hoheisel, J.; Tsopoulidis, N.; Fackler, O.T; Savarino, A.; Andrade-Navarro, M.A; Ott, I.; Lusic, M.; Hadaschik, E.N.; Wölfl, S. Commun. Biol. 2020, 3, 1-12. [Link]
11. In-vitro and in-vivo investigations into the carbene-gold anticancer drug candidates NHC*-Au-SCSNMe₂ and NHC*-Au-S- GLUC against advanced prostate cancer PC3 Walther, W,.; Althagafi, D.; Curran, D.; O’Beirne, C.; Mc Carthy, C.; Ott, I.; Basu, U.; Büttner, B.; Sterner-Kock, A.; Müller-Bunz, H.; Sanchez-Sanz, G.; Zhu, X.; Tacke, M. Anti-Cancer Drugs 2020, 31, 672-683. [Link]
12. Polymeric Encapsulation of Novel Homoleptic Bis(dipyrrinato) Zinc(II) Complexes with Long Lifetimes for Applications as Photodynamic Therapy Photosensitizers Karges, J.;  Basu, U; Blaque, O.; Chao, H.; Gasser, G.  Angew. Chem. Int. Ed. 2019, 58, 14334-14340. [Link]
13. Biological Evaluation of the NIR-Emissive Ruby Analogue as a Photodynamic Therapy Photosensitizer Basu, U.;  Otto, S. ; Heinze, K. ; Gasser, G. Eur. J. Inorg. Chem. 2019, 37-41. [Link]
14. Investigation of photo-activation on ruthenium (II)–arene complexes for the discovery of potential selective cytotoxic agents Basu, U.; , Karges, J.; Chotard, F.; Balan, C.; Le Gendre, P.; Gasser, G. ; Bodio, E. ; Kabbara, R. M. Polyhedron 2019, 172, 22-27. [Link]
15. Orally Administrable Therapeutic Synthetic Nanoparticle for Zika Virus Surnar, B.; Kamran, M.Z.; Shah, A.; Basu, U.; Kolishetti, N.; Deo, S.; Jayaweera, D. T; Daunert, S.; Dhar, S. ACS Nano 2019, 13, 11034-11048. [Link]
16. Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection Surnar, B.;  ^# Basu, U.; ^# Banik, B.; Ahmad, A.; Marples, B.; Dhar, S. Proc. Natl. Acad. Sci. USA 2018, 115, (^# Equal contribution) [Link]
17. A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation Pathak, R. K.;^# Basu, U.;^# Ahmad, A.; Kumar, A.; Ansari, S.; Kolishetti, N.; Wilczek, K.; Ivan, M.; Marples, B.; Dhar, S. Biomaterials 2018, 187, 117-129 (^# Equal contribution) [Link]
18. Iron(III) Complexes of Vitamin B₆ Schiff Base with Boron-Dipyrromethene Pendants for Lysosome-Selective Photocytotoxicity Sahoo, S.; Podder, S.; Garai, A.; Majumdar, S.; Mukherjee, N.; . Basu, U.; Nandi, D.; Chakravarty, A. R. Eur. J. Inorg. Chem 2018, 13, 1522-1532. [Link]
19. Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity Surnar, B.; Kolishetti, N.; Basu, U.; Ahmad, A.; Goka, E.; Marples, B.; Kolb, D.; Lippman, M.; Dhar, S. Biochemistry 2018, 57, 6500-6513. [Link]
20. The Platin-X series: activation, targeting, and delivery Basu, U.; Banik, B.; Wen, R.; Pathak, R. K.; Dhar, S. Dalton Trans. 2016, 45, 12992-13004. [Link]

Publications during PhD research (2010-2016) 

1. Mitochondria-Targeting Iron (III) Catecholates for Photoactivated Anticancer Activity under Red Light Basu, U.; Pant, I.; Kondaiah, P.; Chakravarty, A. R. Eur. J. Inorg. Chem. 2016, 1002-1012. [Link]
2. Photoactive platinum (ii) β-diketonates as dual action anticancer agents Raza, M.K.; Mitra, K.; Shettar, A.   Basu, U.; Kondaiah, P.; Chakravarty, A. R. Dalton Trans. 2016, 45,13234-13243. [Link]
3. Iron (III) complexes of a pyridoxal Schiff base for enhanced cellular uptake with selectivity and remarkable photocytotoxicity Basu, U.; Pant, I.; Hussain, A.; Kondaih, P.; Chakravarty, A. R. Inorg. Chem. 2015, 54, 3748-3758. [Link]
4. Polypyridyl iron (II) complexes showing remarkable photocytotoxicity in visible light Garai, A.;  Basu, U.; Pant, I.; Kondaiah, P.; Chakravarty,  A. R. J. Chem. Sci. 2015, 127, 609-618. [Link]
5. Carbohydrate-appended tumor targeting iron (III) complexes showing photocytotoxicity in red light Basu, U. ; Khan, I.; Hussain, A.; Gole, B.; Kondaiah, P.; Chakravarty, A. R. Inorg. Chem. 2014, 53, 2152-2162. [Link]
6. Iron (III) catecholates for cellular imaging and photocytotoxicity in red light Basu, U.; Pant, I.; Khan, I.; Hussain, A.; Kondaiah, P.; Chakravarty, A. R. Chem. Asian J. 2014, 9, 2494-2504. [Link]
7. Remarkable anticancer activity of ferrocenyl-terpyridine platinum (II) complexes in visible light with low dark toxicity Mitra, K.; Basu, U.; Khan, I.; Maity, B.; Kondaiah, P.; Chakravarty A. R.  Dalton Trans. 2014, 43, 751-763. [Link]
8. Iron (III) benzhydroxamates of dipicolylamines for photocytotoxicity in red light and cellular imaging Garai, A.; Basu, U.; Khan, I.; Hussain, A.; Pant, I.; Kondaiah, P.; Chakravarty, A. R. Polyhedron 2014, 73, 124-132. (Cover Article) [Link]
9. Photodynamic Effect in Near-IR Light by a Photocytotoxic Iron (III) Cellular Imaging Agent Basu, U.  ; Khan, I.; Hussain, A.; Kondaiah, P.; Chakravarty, A. R. Angew. Chem. Int. Ed. 2012, 51, 2658-2661. (VIP Article) [Link]
10. Nuclear targeting terpyridine iron (II) complexes for cellular imaging and remarkable photocytotoxicity Basu, U.; Khan, I.; Koley, D.; Saha, S.; Kondaiah, P.; Chakravarty, A. R. J. Inorg. Biochem. 2012, 116, 77-87. [Link]